Choroid plexus meningioma

Summary

Choroid plexus meningioma (MONDO:0003053) is a disease. A subtype of choroid plexus cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	choroid plexus meningioma
Mondo ID	MONDO:0003053
DOID	DOID:4584
NCIT	C4719
UMLS	C0431118
MedGen	98458
GARD	0023346
Anatomy (UBERON)	UBERON:0001886
Is cancer (heuristic)	no

Also known as: choroid meningioma (morphologic abnormality) · choroid plexus meningioma · choroid plexus meningioma (disease) · meningioma (disease) of choroid plexus · meningioma of the choroid plexus

Disease family

This is a subtype of choroid plexus cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › cardiovascular cancer › vascular cancer › choroid plexus cancer › choroid plexus meningioma

Related subtypes (1): choroid plexus carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.